Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

Merck-Hengrui Pharma Deal Announced Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug ...

Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui Pharmaceuticals’ investigational cardiovascular disease (CVD) drug in a ...

(Bloomberg) -- Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug ... to cardiovascular disease. Eli Lilly & Co., Amgen ...

Under terms of the deal, Merck will gain global rights ... The drug is currently in a Phase II clinical trial in China. 1 “Elevated blood concentrations of Lp(a) provides a well-documented risk factor ...

The deal will give the U.S. drugmaker access to an experimental heart disease drug. “The companies ... Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize ...